Association of the BH3 mimetic ABT-199 (Venetoclax), a more specific BCL-2 inhibitor, with either Imatinib [26] or Nilotinib [27] synergistically induced death of quiescent stem/progenitor primary CML CD34+ cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.